We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK - Free Report) , Broadcom (AVGO - Free Report) , Sanofi (SNY - Free Report) , Equinix (EQIX - Free Report) and American Electric Power (AEP - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Analyst Reports for Merck, Broadcom and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck, Broadcom and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+17.9% vs. +16.1%). The Zacks analyst believes that Merck’s products like Keytruda, Lynparza and Bridion are driving sales.
Keytruda sales are gaining from continued uptake in lung cancer and increased usage in other cancer indications. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also doing well and remain core growth drivers.
However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress and Zepatier remains a concern. Estimates have gone up slightly ahead of Q4 results. Merck has a positive record of earnings surprises in recent quarters.
Shares of Broadcom have gained +7.4% in the past six months against the Zacks Electronics - Semiconductors industry's rise of +20.2%. The Zacks analyst believes that Broadcom is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G.
Further, strong ties with leading OEMs across multiple target markets are expected to help the company to gain key insights into the requirements of customers. Recent multi-year agreements with Apple estimated to be worth $15 billion, hold promise. Moreover, the company intends to strengthen presence in the infrastructure software vertical particularly.
In this regard, acquisition of CA remains extremely significant. Nonetheless, the company faces intensifying competition and integration risks due to frequent acquisitions. Further, the company’s leveraged balance sheet remains a major concern.
Sanofi’s shares have gained +5% over the past three months against the Zacks Large Cap Pharmaceuticals industry's rise of +9.6%. The Zacks analyst believes that Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. Dupixent is now annualizing at around €2 billion in sales and could prove to be key long-term driver.
The performance of the Vaccines and Consumer Healthcare franchises also improved of late. Sanofi’s R&D pipeline is strong with several positive data read-outs and the achievement of regulatory milestones expected in 2020.
However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Estimates have gone down slightly, ahead of Q4 earnings release. Sanofi has a positive record of earnings surprise in the recent quarters.
Other noteworthy reports we are featuring today include Equinix and American Electric Power.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained an impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Merck, Broadcom, Sanofi, Equinix and American Electric Power
For Immediate Release
Chicago, IL – January 28, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK - Free Report) , Broadcom (AVGO - Free Report) , Sanofi (SNY - Free Report) , Equinix (EQIX - Free Report) and American Electric Power (AEP - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Analyst Reports for Merck, Broadcom and Sanofi
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck, Broadcom and Sanofi. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+17.9% vs. +16.1%). The Zacks analyst believes that Merck’s products like Keytruda, Lynparza and Bridion are driving sales.
Keytruda sales are gaining from continued uptake in lung cancer and increased usage in other cancer indications. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also doing well and remain core growth drivers.
However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and on products like Isentress and Zepatier remains a concern. Estimates have gone up slightly ahead of Q4 results. Merck has a positive record of earnings surprises in recent quarters.
Shares of Broadcom have gained +7.4% in the past six months against the Zacks Electronics - Semiconductors industry's rise of +20.2%. The Zacks analyst believes that Broadcom is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G.
Further, strong ties with leading OEMs across multiple target markets are expected to help the company to gain key insights into the requirements of customers. Recent multi-year agreements with Apple estimated to be worth $15 billion, hold promise. Moreover, the company intends to strengthen presence in the infrastructure software vertical particularly.
In this regard, acquisition of CA remains extremely significant. Nonetheless, the company faces intensifying competition and integration risks due to frequent acquisitions. Further, the company’s leveraged balance sheet remains a major concern.
Sanofi’s shares have gained +5% over the past three months against the Zacks Large Cap Pharmaceuticals industry's rise of +9.6%. The Zacks analyst believes that Sanofi’s Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. Dupixent is now annualizing at around €2 billion in sales and could prove to be key long-term driver.
The performance of the Vaccines and Consumer Healthcare franchises also improved of late. Sanofi’s R&D pipeline is strong with several positive data read-outs and the achievement of regulatory milestones expected in 2020.
However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Estimates have gone down slightly, ahead of Q4 earnings release. Sanofi has a positive record of earnings surprise in the recent quarters.
Other noteworthy reports we are featuring today include Equinix and American Electric Power.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained an impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.